Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Faron Pharmaceuticals Oy's enterprise value is €106.33 Mil.
Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-25.66 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-EBITDA for today is -4.14.
The historical rank and industry rank for Faron Pharmaceuticals Oy's EV-to-EBITDA or its related term are showing as below:
FRA:4FR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24 Med: -6.53 Max: -0.58
Current: -4.11
During the past 13 years, the highest EV-to-EBITDA of Faron Pharmaceuticals Oy was -0.58. The lowest was -24.00. And the median was -6.53.
FRA:4FR's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.485
vs FRA:4FR: -4.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Faron Pharmaceuticals Oy (FRA:4FR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Faron Pharmaceuticals Oy's PE Ratio (TTM) for today is calculated as:
Faron Pharmaceuticals Oy's share price for today is €0.467.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.221.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4FR vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-EBITDA falls into.
Faron Pharmaceuticals Oy's current Enterprise Value is €106.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-25.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faron Pharmaceuticals Oy (FRA:4FR) has a EV-to-EBITDA of -4.14 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Faron Pharmaceuticals Oy. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 400 companies in the Biotechnology industry.
Is Faron Pharmaceuticals Oy's EV-to-EBITDA too high?
Faron Pharmaceuticals Oy's current EV-to-EBITDA is -4.14. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 400 companies for EV-to-EBITDA. This places Faron Pharmaceuticals Oy in the lower half of its industry. The industry median EV-to-EBITDA is 13.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Faron Pharmaceuticals Oy. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faron Pharmaceuticals Oy's current EV-to-EBITDA is -4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current EV-to-EBITDA of -4.14. The current EV-to-EBITDA is -4.14. Faron Pharmaceuticals Oy's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current EV-to-EBITDA is -4.14 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
32GF Score
Get the complete analysis for FRA:4FR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4FR has been successfully added to your 
